- Language: English
- 1113 Pages
- Published: July 2012
- Region: Global
Global Human Insulin Market 2011-2015
- Published: July 2012
- Region: Global
- 43 pages
- Infiniti Research Limited
TechNavio's analysts forecast the Global Human Insulin market to grow at a CAGR of -4.02 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant increase in the number of patients suffering from diabetes and diabetes-related diseases worldwide. The Global Human Insulin market has also been witnessing the trend of rapid growth in the APAC region. However, the increased risk of cancer with human insulin use could pose a challenge to the growth of this market.
TechNavio's report, the Global Human Insulin Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Human Insulin market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Bayer Healthcare AG, Eli Lilly & Co., Novo Nordisk A/S, and Sanofi S.A.
Other vendors mentioned in the report: Abbott Laboratories Inc., Wockhardt Ltd., Piramal Healthcare Ltd., Glenmark Pharmaceuticals Ltd., SciGen Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceutical Ltd., Wangbang Pharma Group Corp., and Pfizer Inc.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.
TechNavio today launched its report Global Human Insulin Market 2011-2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said; “The Global Human Insulin market is currently experiencing significant growth in the APAC region, especially in certain countries such as China and India. China is considered to be one of the countries with the largest diabetic populations at present. The prevalence of diabetes in China increased significantly in 2010. Further, India is currently home to tremendous numbers of people suffering from diabetes. Hence, there is significantly high demand for human insulin in certain countries in the APAC region.”
According to the report, there is an increase in innovative biologic drug molecules that increase the demand for human insulin, which is eventually expected to drive the growth of the Global Human Insulin market during the forecast period.
Further, the risk of cancer associated with human insulin use is expected to be one of the main reasons for the decline of human insulin sales during the forecast period.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players. SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
04.1 Global Insulin Market
04.2 Global Human Insulin Market
Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Novo Nordisk A/S
15.2 Eli Lilly and Co.
15.3 Bayer Healthcare AG
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Insulin Market 2011-2015 (US$ billion)
Exhibit 2: Global Insulin Market by Product Segmentation
Exhibit 3: Global Insulin Market by Category Segmentation 2011
Exhibit 4: Global Insulin Market 2011-2015 by Revenue Segmentation (US$ billion)
Exhibit 5: Global Insulin Market 2011-2015 by Segmentation (percentage)
Exhibit 6: Global Human Insulin Market 2011-2015 (US$ billion)
Exhibit 7: Global Human Insulin Market by Geographical Segmentation 2011
Exhibit 8: Estimated Preventable Cases of Diabetes per Year in the US (percentage)
Exhibit 9: Global Human Insulin Market by Vendor Segmentation 2011
Bayer Healthcare AG, Eli Lilly, Novo Nordisk A/S,Sanofi S.A